Faculty introduction, disclosures

Introductory content: defining the context and challenge of ocular allergy Epidemiology Clinical features, presentation, pathophysiology, and allergens  Challenges of diagnosis

Treatment of ocular allergy Goals of therapy Staging of ocular allergy based on type and severity  Available OTC and prescription treatments  · The impact of active ingredients on efficacy and patient comfort · Mechanism of action, adverse effects, and place in therapy of the following agents, taking into account specific disorders (e.g., acute allergic conjunctivitis, SAC, PAC, VKC, etc.): · Mast-cell stabilizers · Antihistamines · Nonsteroidal anti-inflammatory drugs · Dual-action agents · Roles of corticosteroids and calcineurin inhibitors · Additional and novel drug delivery systems · Emerging agents Non-pharmacotherapy Challenges to successful ocular allergy treatment and optimal outcomes  Special populations: pregnancy considerations Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Recall the clinical presentation and optimal strategies for appropriate diagnosis of OA.
• Summarize challenges to the optimal diagnosis and treatment of OA and strategies for overcoming them.
• Identify the currently available and emerging pharmacotherapeutic treatment options for the management of OA.
• Formulate a treatment plan for a patient with an OA.

ACCME Activity #202448523

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Benjamin B. Bert, MD, FACS, Assistant Professor, David Geffen School of Medicine at UCLA, received financial compensation for research from Regeneron and Novartis.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Alcon Vision.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version